Directors' Share Dealing

RNS Number : 9126Z

Hutchison China Meditech Limited

20 March 2017

 

Directors' Share Dealing

London: Monday, March 20, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-

1.   Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in the capital of Chi-Med ("Ordinary Shares") at a price of GBP26.37 per share on March 15, 2017;

2.   Dr Dan Eldar, Non-executive Director, purchased a total of 6,225 American Depositary Shares of the Company ("ADSs", each representing one half of one Ordinary Share) at an average price of US$16.85 per ADS on March 15, 2017;

3.   Dr Karen Ferrante, Independent Non-executive Director, purchased a total of 2,540 ADSs at an average price of US$19.77 per ADS on March 16, 2017; and

4.   Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 10,000 ADSs at an average price of US$19.10 per ADS on March 16, 2017.

Following the above purchases, Mr Carter is interested in 2,800 Ordinary Shares, representing approximately 0.005% of the current issued share capital of Chi-Med; Dr Eldar is interested in 6,225 ADSs, representing approximately 0.005% of the current issued share capital of Chi-Med; Dr Ferrante is interested in 2,540 ADSs, representing approximately 0.002% of the current issued share capital of Chi-Med; and Ms Shih is interested in                50,741 ADSs and 60,000 Ordinary Shares, representing approximately 0.14% of the current issued share capital of Chi-Med.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation. 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Paul Carter
2	Reason for the notification
a)	Position/status	Independent Non-executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hutchison China MediTech Limited
b)	LEI	N/A

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Share of US$1.00 each DI ISIN: KYG4672N1016 ADS ISIN: US44842L1035
b)	Nature of the transaction	Acquisition of 2,800 Ordinary Shares on March 15, 2017 at a price of GBP26.37 per share
c)	Price(s) and volume(s)	Price(s) Volume(s) GBP26.37 2,800
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2017-03-15
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Dan Eldar
2	Reason for the notification
a)	Position/status	Non-executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hutchison China MediTech Limited
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035
b)	Nature of the transaction	Acquisition of 6,225 ADSs on March 15, 2017 at an average price of US$16.85 per ADS
c)	Price(s) and volume(s)	Price(s) Volume(s) US$16.51 3,220 US$17.19 2,600 US$17.33 5 US$17.16 100 US$17.47 100 US$17.48 200
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2017-03-15
f)	Place of the transaction	Nasdaq Stock Market

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Karen Ferrante
2	Reason for the notification
a)	Position/status	Independent Non-executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hutchison China MediTech Limited
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035
b)	Nature of the transaction	Acquisition of 2,540 ADSs on March 16, 2017 at an average price of US$19.77 per ADS
c)	Price(s) and volume(s)	Price(s) Volume(s) US$19.76 1,100 US$19.84 668 US$19.65 372 US$19.85 200 US$19.60 100 US$19.84 100
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2017-03-16
f)	Place of the transaction	Nasdaq Stock Market

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ms Edith Shih
2	Reason for the notification
a)	Position/status	Non-executive Director and Company Secretary
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hutchison China MediTech Limited
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US$1.00 ADS ISIN: US44842L1035
b)	Nature of the transaction	Acquisition of 10,000 ADSs on March 16, 2017 at an average price of US$19.10 per ADS
c)	Price(s) and volume(s)	Price(s) Volume(s) US$19.10 9,908 US$19.02 92
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2017-03-16
f)	Place of the transaction	Nasdaq Stock Market

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

 

Contacts

Investor Enquiries
Christian Hogg, CEO	[phone]
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson	[phone] (Mobile)	[e-mail]
U.S. Based Media Enquiries
Brad Miles, BMC Communications	[phone] (Mobile)	[e-mail]
Susan Duffy, BMC Communications	[phone] (Mobile)	[e-mail]
Investor Relations
Matt Beck, The Trout Group	[phone] (Mobile)	[e-mail]
David Dible, Citigate Dewe Rogerson	[phone] (Mobile)	[e-mail]
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts	[phone]

 

END

 

 

DSHLIFITVIIIFID